Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues – Blood proteins or globulins – e.g. – proteoglycans – platelet...
Reexamination Certificate
2001-09-10
2004-05-04
Chan, Christina (Department: 1644)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
Blood proteins or globulins, e.g., proteoglycans, platelet...
C530S388100, C530S389100
Reexamination Certificate
active
06730779
ABSTRACT:
TECHNICAL FIELD
Throughout this application various publications are referenced within parentheses. The disclosure of these publications in their entireties are hereby incorporated by reference in this application in order to more fully describe the state of the art to which this invention pertains.
BACKGROUND OF THE INVENTION
The present invention relates generally to apoptosis or, programmed cell death, and more particularly, to novel aspartate-specific cysteine proteases which can be used to modulate apoptosis for the therapeutic treatment of human diseases.
Apoptosis is a normal physiological process of cell death that plays a critical role in the regulation of tissue homeostasis by ensuring that the rate of new cell accumulation produced by cell division is offset by a commensurate rate of cell loss due to death. It has now become clear that disturbances in apoptosis, also referred to as physiological cell death or programmed cell death, that prevent or delay normal; cell turnover can be just a important to the pathogenesis of diseases as are known abnormalities in the regulation of proliferation and the cell cycle. Like cell division, which is controlled through complex interactions between cell cycle regulatory proteins, apoptosis is similarly regulated under normal circumstances by the interaction of gene products that either induce or inhibit cell death.
The stimuli which regulate the function of these apoptotic gene products include both extracellular and intracellular signals. Either the presence or removal of a particular stimuli can be sufficient to evoke a positive or negative apoptotic signal. For example, physiological stimuli that prevent or inhibit apoptosis include, for example, growth factors, extracellular matrix, CD40 ligand, viral gene products neutral amino acids, zinc, estrogen and androgens. In contrast, stimuli which promote apoptosis include growth factors such as tumor necrosis factor (TNF), Fas, and transforming growth factor &bgr; (TGF&bgr;), neurotransmitters, growth withdrawal, loss of extracellular matrix attachment, intracellular calcium and glucocorticoids, for example. Other stimuli, including those of environmental and pathogenetic origins, also exist which can either induce or inhibit programmed cell death. Although apoptosis is mediated by diverse signals and complex interactions of cellular gene products, the results of these interactions ultimately feed into a cell death pathway that is evolutionarily conserved between humans and invertebrates.
Several gene products which modulate the apoptotic process have now been identified. Although these products can in general be separated into two basic categories, gene products from each category can function to either inhibit or induce programmed cell death. One family of gene products are those which are members of the Bcl-2 family of proteins. Bcl-2, is the best characterized member of this family and inhibits apoptosis when overexpressed in cells. Other members of this gene family include, for example, Bax, Bak, Bcl-x
L
, Bcl-x
S
, and Bad. While some of these proteins can prevent apoptosis others augment apoptosis (e.g., Bcl-x
S
and Bak, respectively.)
A second family of gene products, the aspartate-specific cysteine proteases (ASCPs), are related genetically to the
C. elegans
ced-3 gene product which was initially shown to be required for programmed cell death in the roundworm,
C. elegans
. The ASCPs family of proteases include human ICE (interleukin-1-&bgr; converting enzyme), ICH-1
L
, ICH-1
S
, CPP32, Mch2, Mch3, ICH-2 and ICE
rel
III. Among the common features of these gene products is that 1) they are cysteine proteases with specificity for substrate cleavage at Asp-x bonds, 2) they share a conserved pentapeptide sequence (QACRG; Seq. Id. No. 11) within the active site and 3) they are synthesized as proenzymes that require proteolytic cleavage at specific aspartate residues for activation of protease activity. Cleavage of the proenzyme produces two polypeptide protease subunits of approximately 20 kD (p20) and 10 kD (p10) which, in the case of ICE, combine non-covalently to form a tetramer comprised of two p20:p10 heterodimers. Although these proteases, when expressed in cells, induce cell death, several alternative structural forms of these proteases, such as ICE&dgr;, ICE&egr;, ICH-1
S
and Mch2&bgr;, actually function to inhibit apoptosis.
In addition to the Bcl-2 and ASCP gene families which play a role in apoptosis in mammalian cells, it has become increasingly apparent that other gene products exist which are important in mammalian cell death and which have yet to be identified. For example, in addition to Ced-3, another
C. elegans
gene known as Ced-4 exists which is also required for programmed cell death in
C. elegans
. However, mammalian homologies of this protein remain elusive and have not yet been identified. Further, it is ambiguous as to whether other genes exist which belong to either of the above two apoptotic gene families or what role they may play in the programmed cell death pathway. Finally, it is unclear what the physiological control mechanisms are which regulate programmed cell death or how the cell death pathways interact with other physiological processes within the organism. For example, recently it has been suggested that the cytotoxic T-lymphocytes mediate their destructive function by inducing apoptosis in their target cells.
Apoptosis functions in maintaining tissue homeostasis in a range of physiological processes such as embryonic development, immune cell regulation and normal cell turnover. Therefore, the dysfunction, or loss of regulated apoptosis can lead to a variety of pathological disease states. For example, the loss of apoptosis can lead to the pathological accumulation of self-reactive lymphocytes such as that occurring with many autoimmune diseases. Inappropriate loss of apoptosis can also lead to the accumulation of virally infected cells and of hyperproliferative cells such as neoplastic or tumor cells. Similarly, the inappropriate activation of apoptosis can also contribute to a variety of pathological disease states including, for example, acquired immunodeficiency syndrome (AIDS), neurodegenerative diseases and ischemic injury. Treatments which are specifically designed to modulate the apoptotic pathways in these and other pathological conditions can change the natural progression of many of these diseases.
Thus, there exists a need to identify new apoptosis genes and their gene products and for methods of modulating this process for the therapeutic treatment of human diseases. The present invention satisfied this need and provides related advantages as well.
SUMMARY OF THE INVENTION
The invention provides an isolated gene encoding Mch4 or an isolated gene encoding Mch5 as well as functional fragments thereof. Also provided are isolated nucleic acid sequences encoding Mch4 or Mch5 or functional fragment thereof. The gene or nucleic acid sequences can be single or double stranded nucleic acids corresponding to coding or non-coding strands of the Mch4 or Mch5 nucleotide sequences. Also provided are genes and nucleic acids encoding functional fragments such as the FADD-like domains Mch4A, Mch4B, or Mch5A and Mch5B. Isolated Mch4 or Mch5 polypeptides or functional fragments thereof including the FADD-like domains Mch4A, Mch4B, Mch5A and Mch5B are also provided.
REFERENCES:
patent: 5605826 (1997-02-01), Wright et al.
patent: WO 97/03998 (1997-02-01), None
Barinaga, M., “Cell Suicide: By ICE, Not Fire,”Science 26: 754-756, 1994.
Black et al., “Activation of Interleukin-1&bgr; by a Co-induced Protease,”FEBS Letters 247: 386-390, 1989.
Boldin et al., “A Novel Protein That Interacts with the Death Domain of Fas/AP01 Contains a Sequence Motif Related to the Death Domain,”J. Biol. Chem. 270(14): 7795-7798, 1995.
Boldin et al., “Involvement of MACH, a novel MOR1-FADD-interacting protease, in Fas-APO-1- and TNF receptor-induced cell death,”Cell 85(6): 803-815, 1996.
Cerretti et al., “Molecular Cloning of the Interleukin-1&bgr; Converting E
Alnemri Emad S.
Armstrong Robert
Fernandes-Alnemri Teresa
Litwack Gerald
Tomaselli Kevin
Belyavskyl Michail A
Chan Christina
IDUN Pharmaceuticals Inc.
Seed Intellectual Property Law Group PLLC
LandOfFree
Antibody that specifically binds an Mch4 polypeptide does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Antibody that specifically binds an Mch4 polypeptide, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Antibody that specifically binds an Mch4 polypeptide will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3246400